MUNICH, December 13, 2011 /PRNewswire/ --
Pooled results of the STARS E-III and STARS J-V studies presented at the
2011 American Society of Hematology (ASH) Annual Meeting
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the results of a pooled analysis showing that edoxaban*, a direct oral once-daily factor Xa inhibitor, significantly reduced the risk of developing venous thromboembolism (VTE) following total knee or hip arthroplasty when compared to enoxaparin.[1] Patients receiving edoxaban had a lower incidence of a composite of deep vein thrombosis (DVT) and pulmonary embolism (PE) than those treated with enoxaparin (5.1% vs. 10.7%, P<0.001, Relative Risk Reduction [RRR] 52.7%, Absolute Risk Reduction [ARR] -5.6%), an effect that was shown without a statistically significant difference in bleeding between the groups.[1]
The analysis drew data from two randomised, double-blind, double-dummy, phase III studies (STARS E-III and STARS J-V) of 1,326 Japanese and Taiwanese patients[1] who had underwent total knee arthroplasty (TKA) or total hip arthroplasty (THA).[2,3] Results were presented in an oral session at the 53rd Annual Meeting of the American Society of Hematology in San Diego, USA.[1]
"Total hip and knee arthroplasty surgeries place patients at a higher risk of DVT, which can lead to thromboembolic disease such as PE," said Dr. Takeshi Fuji, Head of Orthopaedic Surgery, Osaka Koseinenkin Hospital, Osaka Japan. "As the number of these surgeries increases and the incidence of VTE is expected to double by the year 2050,[4] it will become increasingly important for physicians to have a number of treatment options to prevent DVT and PE following these surgeries."
The incidence of major and Clinically Relevant Non-Major (CRNM) bleeding events in the edoxaban* and enoxaparin groups was 4.6% vs. 3.7%, respectively (P=0.427).[1] A further subgroup analysis of major and CRNM bleeding indicated no significant difference between edoxaban and enoxaparin in any of the patient subgroups evaluated, based on age, weight, or creatinine clearance.[1]
Patients enrolled in the STARS E-III (Japanese and Taiwanese patients) and STARS J-V (Japanese patients) studies were randomised to receive either oral edoxaban 30 mg once daily or subcutaneous enoxaparin 20 mg (2,000 IU) twice daily for 11-14 days,[2,3] in line with standard clinical practice in Japan.
"We are pleased to see positive outcomes with edoxaban in this patient population," said Dr. Kazunori Hirokawa, Global, Head of R&D Unit, Daiichi Sankyo Co., Ltd. "These results further support the safety and efficacy of edoxaban in the prevention of DVT and PE following major orthopaedic surgery. Daiichi Sankyo remains committed to developing edoxaban in our global clinical trials program."
About Edoxaban
Edoxaban is a once-daily oral anticoagulant that directly inhibits Factor Xa, an important factor in the coagulation process.[5] Edoxaban is currently available only in Japan, licensed for the prevention of venous thromboembolism (VTE) in patients undergoing total knee arthroplasty, total hip arthroplasty and hip fracture surgery.[6] Daiichi Sankyo continues to develop edoxaban at a global level as a potential new treatment for stroke prevention in atrial fibrillation, and the treatment and prevention of recurrent VTE. Notably, Daiichi Sankyo has more than 25 years experience conducting research in the area of Factor Xa inhibition and was the first company to study these compounds in humans.
About the Pooled STARS Analysis
The analysis drew data from two Phase III comparative studies, STARS E-III and STARS J-V.[2,3]
- The STARS E-III study was a double-blind, enoxaparin-controlled,
randomised study comparing edoxaban 30 mg once daily and enoxaparin 20 mg (2,000 IU)
in the prevention of VTE in a total of 716 Japanese and Taiwanese patients undergoing
TKA.[2]
- The STARS J-V study was a double-blind, enoxaparin-controlled, randomised
study comparing edoxaban 30 mg once daily and enoxaparin 20 mg (2,000 IU) in the
prevention of VTE in 610 Japanese patients undergoing THA.[3]
Both studies supported the March 2010 edoxaban New Drug Application (NDA) in Japan seeking approval for the prevention of VTE after major orthopaedic surgery. In the studies, edoxaban was initiated six to 24 hours after surgery; enoxaparin was initiated 24 to 36 hours after surgery,[2] the standard of care in Japan. The primary efficacy outcome in both studies was the composite of symptomatic and asymptomatic DVT and PE.[2,3] The principal safety outcome was incidence of major and clinically relevant non-major bleeding.[2,3]
About Venous Thromboembolism
VTE is the term for the generation of a blood clot within a vein, or the subsequent breaking off of that clot into a pulmonary (lung) artery.[7,8] Deep vein thrombosis (DVT) and pulmonary embolism (PE) are the two sub-types of VTE.[7] DVT is a blood clot anywhere in the deep veins of the legs, pelvis or arms.[9] PE is a clot that detaches from the vein and travels to the lungs,[9] lodging in the pulmonary arteries causing a potentially fatal condition.[9,10] PE is often accompanied by DVT and a DVT can develop into a PE suddenly.[10]
Patients with diagnosed VTE are treated for three to six months (and sometimes even longer) based on their individual risk profile to prevent a second (recurrent) DVT or PE.[10] VTE is the cause of significant mortality; 30% of people with VTE die within one month of diagnosis and about 25% of those with PE experience sudden death.[11] Additionally, about 30% of those affected will experience a recurrence of DVT/PE within 10 years of the initial DVT/PE diagnosis.[11]
About Daiichi Sankyo
The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimise growth opportunities across the value chain.
The company's world headquarters are in Tokyo. Its European base is located in Munich. Daiichi Sankyo Europe has affiliates in 12 European countries in addition to a global manufacturing site located in Pfaffenhofen, Germany.
For more information, please visit: http://www.daiichisankyo.com/ [http://www.daiichisankyo.com ] or http://www.daiichi-sankyo.eu/ [http://www.daiichi-sankyo.eu ]
Forward-looking statements
(CONTINUA)
